FOXP3 and non-Hodgkin lymphoma: Early clinical investigations employing IL-2 as an adjuvant for CAR T cell therapy in non-Hodgkin lymphoma demonstrated an increase in the frequency of FOXP3+ Treg cells (185, 186).